| Emicizumab prophylaxis in hemophilia A with inhibitors J Oldenburg, JN Mahlangu, B Kim, C Schmitt, MU Callaghan, G Young, ... New England Journal of Medicine 377 (9), 809-818, 2017 | 1190 | 2017 |
| Emicizumab prophylaxis in patients who have hemophilia A without inhibitors J Mahlangu, J Oldenburg, I Paz-Priel, C Negrier, M Niggli, ME Mancuso, ... New England Journal of Medicine 379 (9), 811-822, 2018 | 772 | 2018 |
| UPR pathways combine to prevent hepatic steatosis caused by ER stress-mediated suppression of transcriptional master regulators DT Rutkowski, J Wu, SH Back, MU Callaghan, SP Ferris, J Iqbal, R Clark, ... Developmental cell 15 (6), 829-840, 2008 | 672 | 2008 |
| A phase 3 randomized trial of voxelotor in sickle cell disease E Vichinsky, CC Hoppe, KI Ataga, RE Ware, V Nduba, A El-Beshlawy, ... New England Journal of Medicine 381 (6), 509-519, 2019 | 650 | 2019 |
| Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia L Noetzli, RW Lo, AB Lee-Sherick, M Callaghan, P Noris, A Savoia, ... Nature genetics 47 (5), 535-538, 2015 | 359 | 2015 |
| Valoctocogene roxaparvovec gene therapy for hemophilia A MC Ozelo, J Mahlangu, KJ Pasi, A Giermasz, AD Leavitt, M Laffan, ... New England Journal of Medicine 386 (11), 1013-1025, 2022 | 342 | 2022 |
| Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies MU Callaghan, C Negrier, I Paz-Priel, T Chang, S Chebon, M Lehle, ... Blood, The Journal of the American Society of Hematology 137 (16), 2231-2242, 2021 | 266 | 2021 |
| Two-year outcomes of valoctocogene roxaparvovec therapy for hemophilia A J Mahlangu, R Kaczmarek, A Von Drygalski, S Shapiro, SC Chou, ... New England Journal of Medicine 388 (8), 694-705, 2023 | 160 | 2023 |
| Laboratory monitoring in emicizumab-treated persons with hemophilia A J Müller, I Pekrul, B Pötzsch, B Berning, J Oldenburg, M Spannagl Thrombosis and haemostasis 119 (09), 1384-1393, 2019 | 101 | 2019 |
| The effect of emicizumab prophylaxis on health‐related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study J Oldenburg, JN Mahlangu, W Bujan, P Trask, MU Callaghan, G Young, ... Haemophilia 25 (1), 33-44, 2019 | 101 | 2019 |
| Electron spin resonance of DNA irradiated with a heavy-ion beam (16O8+): Evidence for damage to the deoxyribose phosphate backbone D Becker, Y Razskazovskii, MU Callaghan, MD Sevilla Radiation research 146 (4), 361-368, 1996 | 100 | 1996 |
| Cost-effectiveness and budget impact of emicizumab prophylaxis in haemophilia A patients with inhibitors PA Cortesi, G Castaman, G Trifirò, SS Creazzola, G Improta, G Mazzaglia, ... Thrombosis and Haemostasis 120 (02), 216-228, 2020 | 96 | 2020 |
| Global seroprevalence of pre-existing immunity against AAV5 and other AAV serotypes in people with hemophilia A R Klamroth, G Hayes, T Andreeva, K Gregg, T Suzuki, IH Mitha, ... Human Gene Therapy 33 (7-8), 432-441, 2022 | 93 | 2022 |
| Genotype-phenotype correlation in combined deficiency of factor V and factor VIII B Zhang, M Spreafico, C Zheng, A Yang, P Platzer, MU Callaghan, Z Avci, ... Blood, The Journal of the American Society of Hematology 111 (12), 5592-5600, 2008 | 92 | 2008 |
| Pharmacokinetics and pharmacodynamics of emicizumab in persons with hemophilia A with factor VIII inhibitors: HAVEN 1 study C Schmitt, JI Adamkewicz, J Xu, C Petry, O Catalani, G Young, C Negrier, ... Thrombosis and haemostasis 121 (03), 351-360, 2021 | 89 | 2021 |
| Clinical predictors of poor outcomes in patients with sickle cell disease and COVID-19 infection CP Minniti, AU Zaidi, M Nouraie, D Manwani, GD Crouch, AS Crouch, ... Blood advances 5 (1), 207-215, 2021 | 80 | 2021 |
| Celastrol induces unfolded protein response-dependent cell death in head and neck cancer AM Fribley, JR Miller, AL Brownell, DM Garshott, Q Zeng, TE Reist, ... Experimental cell research 330 (2), 412-422, 2015 | 65 | 2015 |
| The role of emicizumab, a bispecific factor IXa-and factor X-directed antibody, for the prevention of bleeding episodes in patients with hemophilia A T Knight, MU Callaghan Therapeutic advances in hematology 9 (10), 319-334, 2018 | 62 | 2018 |
| Novel therapeutics for hemophilia and other bleeding disorders MU Callaghan, R Sidonio, SW Pipe Blood, The Journal of the American Society of Hematology 132 (1), 23-30, 2018 | 59 | 2018 |
| Inhibitor recurrence after immune tolerance induction: a multicenter retrospective cohort study A Antun, PE Monahan, MJ Manco‐Johnson, MU Callaghan, M Kanin, ... Journal of Thrombosis and Haemostasis 13 (11), 1980-1988, 2015 | 58 | 2015 |
Johannes OldenburgProfessor for Transfusion Medicine, University BonnVerified email at ukb.uni-Bonn.de
